Neurofilament light: a possible prognostic biomarker for treatment of vascular contributions to cognitive impairment and dementia

Table 1 Table demonstrating cytokine and chemokine levels of whole brain lysate

	Cytokine and chemokine, relative expression (pg/ml)						p values
Cytokines	Control-Saline (n=5-6)	HF-Saline (n=6)	HF-A50 (n=6-7)	HF-P50 (n=6-7)	HF-A500 (n=7)	HF-P500 (n=7)	Control-Saline vs. HF-Saline	HF-Saline vs. HF-P50	HF-Saline vs. HF-A50	HF-Saline vs. HF-P500	HF-Saline vs. HF-A500
IL-1α	92.8 ±5.9	74.7 ±5.4	95.6 ±8.4	103.7 ± 8.1	95.6 ± 5.5	65.4 ±9.7	0.048*	0.027*	ns	ns	0.040*
IL-2	46.8 ±1.1	38.4 ±1.7	47.8 ±3.0	54.3 ± 3.5	50.9 ± 1.9	40.9 ±4.6	0.015*	0.013*	ns	ns	0.002*
IL-5	59.5 ±14.0	28.0 ±9.2	62.6 ±3.9	62.6 ±3.9	53.2 ±2.7	41.7 ±4.9	ns	0.020*	0.026*	ns	ns
IL-13	481.1 ±33.4	385.9 ±14.8	529.9 ±38.6	543.8 ±15.6	510.0 ±17.3	394.0 ±47.6	ns	<0.0001*	0.036*	ns	0.001*
IL-17	40.0 ±1.7	32.4 ±1.1	44.1 ± 2.8	43.0 ±1.9	42.0 ±1.1	35.2 ±4.6	0.021*	0.004*	0.020*	ns	0.0003*
IL-10	45.5 ±4.4	32.1 ±1.1	42.2 ±3.2	40.8 ±2.5	43.8 ±4.2	40.4 ±1.5	0.049*	0.023*	ns	0.005*	ns

IL-1α, IL-2, IL-5, IL-13, IL-17, and IP-10, mean, standard error and number of samples are provided for the following treatment groups: Control-Saline, HF-Saline, HF-A50 (Ang-(1–7), Ang-(1–7)50 ug/kg), HF-P50 (PNA5 50 ug/kg), HF-A500 (Ang-(1–7)500 ug/kg), and HF-P500 (PNA5 500ug/kg). Significant difference between treatment groups and HF-Saline are provided, *Indicates significance, p < 0.05, (ANOVA, Dunnett’s post hoc), ns not significant)

ISSN: 1742-2094